HQ Team
June 28, 2025: World leaders have pledged $9 billion to support Gavi, the Vaccine Alliance, for the next five years after the US administration terminated its funding, arguing the organisation did not take vaccine safety seriously.
The $9-billion pledge came from leaders at the “Health and Prosperity through Immunisation” global summit in Brussels. Gavi’s target budget for 2026 through 2030 is ā¬10.2 billion ($12 billion), according to a statement from the European Commission.
Leaders also committed ā¬3.8 billion ($4.5 billion) in complementary financing from development finance institutions in support of country systems and accelerated access to vaccines and cost savings of up to ā¬170.6 million ($200 million) from manufacturers.
They also pledged more than ā¬127 million ($149 million) in private sector partnerships focused on vaccine delivery.
Other innovation and supply commitments will boost equitable access to critical vaccines around the globe and a range of private-sector partnerships aimed at transforming immunisation systems in lower-income countries, including a ā¬34.1 million ($40 million) anchor commitment toward an Innovation Scale-Up Fund, according to the statement.
New donors
The summit, co-hosted by the European Union, Gates Foundation, and Gavi, in partnership with Global Citizen, was attended by representatives of 55 donor and implementing countries ā including 10 heads of state and government and 24 ministers ā as well as leaders from multilateral institutions, civil society, private sector and vaccine industry.
The Vaccine Alliance, a public-private partnership that helps vaccinate more than half the worldās children against some of the worldās deadliest diseases, brings together developing countries and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Gates Foundation and other private sector partners.
In addition to the co-hosts, the Summit saw new donors step forward to support Gavi’s next strategic cycle (2026-2030). āWith some of Gavi’s existing donors unable to announce commitments due to a need to align pledging with their domestic budgetary cycles, this broad base of support will provide critical momentum for Gavi as it continues to mobilise resources in pursuit of its ā¬10.2 billion fundraising target.ā
Ursula von der Leyen, President of the European Commission, said: “Investing in health is investing in our shared future. Our work with Gavi saves lives. For over 20 years, we have stood side by side, with the European Union contributing overĀ ā¬3.2 billion to vaccinate more than 1 billion children against deadly diseases. But millions still need this vital protection.ā
During the summit, Gavi was able to secure commitments from some of the worldās most important vaccine manufacturers, who announced initiatives to improve access to critical vaccines against diseases like cervical cancer, Ebola, malaria, meningitis, pneumonia and rotavirus.Ā
Price reductions
Price reductions, made possible by manufacturers passing on lower input costs, could enable savings for Gavi-supported programmes of up to $200 million by 2030, according to a statement from Gavi.Ā
Bharat Biotech and GSK announced that the price of the RTS, S/AS01 malaria vaccine, for children in endemic countries, would be reduced by Bharat Biotech by more than half to less than $5. GSK announced that a reduction in unit costs and increased production capacity of the malaria vaccine due to enhanced manufacturing efficiencies will generate cost savings to Gavi of up to ā¬20 million, supporting Gaviās efforts to reach 50 million more children with the malaria vaccine in 2025ā2030.
The Serum Institute of India will continue to offer the most affordable pneumococcal conjugate vaccine containing the most relevant serotypes, at $2 per dose to Former Gavi-eligible countries, and consistently below $4 per dose to never Gavi-eligible MICs, through 2030.
āIn a constrained budget environment, itās even more important to focus aid funding on the investments that really work. And Gavi is exactly that,ā said Bill Gates, chair of the Gates Foundation. āI donāt know of anything with a higher impact per dollar in terms of saving and improving lives. Gavi is one of the best investments Iāve ever madeāand one of the best investments countries can make today in the worldās future,āĀ
Antonio Costa, president of the European Council, said: āWe have to ensure that every person, everywhere, has access to vaccines through Gavi. We are investing not just in vaccines, but in the preparedness and resilience of health systems worldwide. Together with our partners, we are building a more secure and equitable global health architecture. The EU remains firm in its commitment to leaving no one behind.ā
